Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akynzeo vs Standard of Care for CINV in France
NCT03831633Phase 4Unknown
- Sponsor
- CSL Vifor
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chemotherapy-induced nausea and vomiting (CINV) comparing AKYNZEO with Standard of Care (2 arms). Primary endpoint: Anti-emetic response (Complete Response). Status: unknown.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03831633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831633.